Diluted EPS came in at $-0.58, beat the $-0.78 consensus by $0.20.
Trailing eight quarters through Q3 2024
Common questions about ALX Oncology Holdings Inc.'s Q3 2024 earnings report.
ALX Oncology Holdings Inc. (ALXO) reported Q3 2024 earnings on November 7, 2024 before market open.
ALX Oncology Holdings Inc. reported diluted EPS of $-0.58 for Q3 2024.
EPS beat the consensus estimate of $-0.78 by $0.20.
You can read the 10-Q periodic report (0000950170-24-123290) directly on SEC EDGAR. The filing index links above go to sec.gov.